

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

---

PENNSYLVANIA EMPLOYEE BENEFIT )  
TRUST FUND, on behalf of itself and all )  
others similarly situated, JOSEPH )  
MACKEN, and COMMISSIONER LINDA )  
A. WATTERS )  
Plaintiffs, )  
v. ) Civ. No. 05-075-SLR  
ZENECA, INC. and ASTRAZENECA ) (Lead Case)  
PHARMACEUTICALS, LP, )  
Defendants. )

---

**DEFENDANTS' APPENDIX IN SUPPORT OF THEIR MOTION TO DISMISS**

OF COUNSEL:

Peter I. Ostroff  
Mark E. Haddad  
Alycia A. Degen  
Joshua E. Anderson  
SIDLEY AUSTIN BROWN & WOOD LLP  
555 West Fifth Street, Suite 4000  
Los Angeles, CA 90013  
(213) 896-6000

MORRIS, NICHOLS, ARSHT & TUNNELL  
Jack B. Blumenfeld (#1014)  
R. Judson Scaggs, Jr. (#2676)  
Natalie J. Haskins (#4472)  
1201 North Market Street  
P. O. Box 1347  
Wilmington, DE 19899-1347  
(302) 658-9200  
*Attorneys for Defendants*

John W. Treece  
Maja C. Eaton  
Richard D. Raskin  
SIDLEY AUSTIN BROWN & WOOD LLP  
Bank One Plaza  
10 South Dearborn Street  
Chicago, IL 60603  
(312) 853-7000  
*Attorneys for Defendants*

July 1, 2005

Defendants AstraZeneca Pharmaceuticals, L.P. and Zeneca Inc. respectfully submit this Appendix in Support of their Motion to Dismiss.

**TAB**

**STATUTES**

|                 |   |
|-----------------|---|
| 21 U.S.C. § 321 | 1 |
| 21 U.S.C. § 331 | 2 |
| 21 U.S.C. § 352 | 3 |
| 21 U.S.C. § 353 | 4 |
| 21 U.S.C. § 355 | 5 |

**FEDERAL REGULATIONS**

|                     |    |
|---------------------|----|
| 21 C.F.R. § 10.25   | 6  |
| 21 C.F.R. § 201.56  | 7  |
| 21 C.F.R. § 201.57  | 8  |
| 21 C.F.R. § 201.100 | 9  |
| 21 C.F.R. § 202.1   | 10 |
| 21 C.F.R. § 310.3   | 11 |
| 21 C.F.R. § 312.21  | 12 |
| 21 C.F.R. § 314.50  | 13 |
| 21 C.F.R. § 314.81  | 14 |
| 21 C.F.R. § 314.105 | 15 |
| 21 C.F.R. § 314.125 | 16 |
| 21 C.F.R. § 314.126 | 17 |

**FEDERAL REGISTER**

|  |    |
|--|----|
| 60 Fed. Reg. 42,581-82 (Aug. 16, 1995) | 18 |
|--|----|

**OTHER AUTHORITIES**

|                                |    |
|--------------------------------|----|
| 3 Trade Reg. Rep. (CCH) ¶ 7765 | 19 |
|--------------------------------|----|

**TAB**

|  |    |
|--|----|
| <i>Working Agreement Between FTC and Food and Drug Administration,</i><br>4 Trade Reg. Rep (CCH) ¶ 9851 (1971)   | 20 |
| FDA Division of Drug Marketing, Advertising, and Communications Frequently Asked Questions ( <a href="http://www.fda.gov/cder/ddmac/FAQS.HTM">http://www.fda.gov/cder/ddmac/FAQS.HTM</a> )   | 21 |
| Letter from Thomas W. Abrams, Director, Division of Drug Marketing, Advertising and Communications, to Fred Hassan, President and CEO, Pharmacia Corp. (Feb. 1, 2001) ( <a href="http://www.fda.gov/cder/warn/2001/DD8432.pdf">http://www.fda.gov/cder/warn/2001/DD8432.pdf</a> )  | 22 |
| FDA, <i>Guidance for Industry: Clinical Studies Section of Labeling for Prescription Drugs and Biologics – Content and Format</i> (July 2001) (DRAFT) ( <a href="http://www.fda.gov/guidance/1890dft.htm">http://www.fda.gov/guidance/1890dft.htm</a> )  | 23 |
| Statement of Janet Woodcock, M.D. before the Sen. Special Comm. on Aging, July 22, 2003 ( <a href="http://www.hhs.gov/asl/testify/t030722b.html">www.hhs.gov/asl/testify/t030722b.html</a> )   | 24 |
| Letter from Lisa L. Stockbridge, Regulatory Review Officer, Division of Drug Marketing, Advertising, and Communications, to Vincent DeStefano, Associate Director of Regulatory Affairs, Novartis (Dec. 3, 2002) ( <a href="http://www.fda.gov/cder/warn/2002/10972.pdf">http://www.fda.gov/cder/warn/2002/10972.pdf</a> ) | 25 |

#472554